Selank Half-Life & Stability
Part of the full Selank guide - a synthetic tuftsin-analogue heptapeptide reference compound, identity-verified with a COA on every vial.
In brief
Stability and persistence for Selank are framed here from the one peptide-specific property in the entry - prolyl-endopeptidase resistance from the engineered PGP tail - combined with general principles that apply to short peptides as a class. Where a precise Selank-specific half-life or degradation rate is not in the provided data, that absence is stated rather than filled in.
The detail
A closer look
01
The peptide-specific stability feature
The entry's explicit stability claim is structural, not numeric: the C-terminal Pro-Gly-Pro tail resists cleavage by prolyl endopeptidases, and this markedly extends Selank's stability over native tuftsin in research models. In mechanistic terms, prolyl endopeptidases attack proline-containing peptide bonds, which are the principal vulnerability of a proline-rich sequence like Selank's (Thr-Lys-Pro-Arg-Pro-Gly-Pro). By appending a protected PGP motif to the tuftsin core, the design blunts that dominant degradation route, which is the entry's stated basis for Selank persisting longer than unmodified tuftsin. The entry does not provide a numeric half-life, clearance rate, or degradation constant, so no specific time value should be inferred.
02
General peptide-class storage and degradation principles
Beyond the documented enzymatic-resistance feature, the entry supplies no Selank-specific pharmacokinetic constants, so the following are general considerations for short peptides handled in the laboratory and are clearly labeled as general. Lyophilized peptide powders are typically the most stable form and are kept cold and dry until reconstitution; once dissolved in aqueous solvent, short peptides are generally less stable than in the solid state and are protected from repeated temperature cycling and prolonged ambient exposure. Enzymatic hydrolysis (the very route the PGP tail is engineered to resist), as well as moisture and oxidation, are the usual degradation pathways for peptides of this size. These are class-level expectations, not measured Selank values.
03
What is not in the provided data
To stay within the entry, it must be stated that no peptide-specific half-life, in-solution shelf-life figure, storage temperature, or stability time-course for Selank is present in the source record. The only stability statement available is qualitative - improved resistance to prolyl-endopeptidase cleavage and consequently greater stability than native tuftsin in research models, together with the related report of improved blood-brain-barrier permeability. Any quantitative stability window used in a laboratory should come from that lab's own validation, not from this entry.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Selank is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.